Diagnostics firm rejects Escalon stock offer

London-The board of Drew Scientific Group PLC, a diagnostics company specializing in the design, manufacture, sale, and distribution of analytical systems for laboratory testing, has rejected Escalon Medical Corp.'s offer to trade its stock for Drew shares.

Related Videos

View All

Related Content

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Related Content

---

Eyenuk gets greenlight to market AI screening system in European Union

Article

---

Commercial real estate and your practice, part two with Colin Carr

Podcast

---

Study: Retina specialists gain awareness of biosimilars

Article

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcast

---

Diagnosis and treatment: Manage dry eye with these tips

Article

---

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

Article